Graybug Vision to Participate in Upcoming Industry Conferences

REDWOOD CITY, Calif.--()--Graybug Vision, Inc., a venture-stage pharmaceutical company committed to developing potentially transformative therapies for ocular diseases including wet age-related macular degeneration (AMD) and glaucoma, today announced that Jeffrey L. Cleland, Ph.D., President and CEO, will be presenting at the following upcoming industry conferences:

  • Glaucoma360
    Panel: New Horizons in Glaucoma Drug Delivery
    Palace Hotel, San Francisco, CA
    Friday, February 9 at 1:12 pm – 2:30 pm

Jeffrey L. Cleland, PhD., President and CEO, will present a corporate overview and discuss its Phase 1/2 clinical trial of GB-102 in wet AMD as well as other near-term milestones. Dr. Cleland noted, “We are excited to share with the glaucoma community at Glaucoma360 that we have developed a potential best-in-class glaucoma agent combined with our depot delivery technology to provide greater than 40% sustained intraocular pressure (IOP) reduction for up to 6 months after a single administration.” Glaucoma is a leading cause of blindness worldwide. Reduction in elevated IOP is the only proven treatment to reduce progression of disease.

Graybug Vision has two products in development for the treatment of ocular diseases. Its lead product, GB-102, is a novel injectable depot formulation containing a compound that blocks angiogenesis pathways through multiple receptors (e.g., VEGFR) for the potentially twice per year treatment of wet AMD. A Phase 1/2 study of GB-102 in wet AMD patients has completed enrollment in the first two cohorts and enrollment in the final two cohorts is progressing well. To date, there have been no dose limiting toxicities, inflammation, or serious ocular adverse events noted after injection of GB-102. A presentation of the data from the open label part of this study is planned in Q4 2018. A second-generation product, GB-103, for potential once per year treatment of wet AMD is also in development with a presentation scheduled at ARVO 2018.

About Wet Age-related Macular Degeneration (wet AMD)

Wet (neovascular) age-related macular degeneration, is the leading cause of blindness in the developed world in individuals aged 50 years or older. It is caused by the formation of abnormal and leaky new blood vessels behind the retina, termed choroidal neovascularization. The leakage of fluid and protein from the vessels, causes retinal degeneration and leads to severe and rapid loss of vision. According to the National Eye Institute, the prevalence of wet AMD among adults 40 years or older in the U.S. alone is estimated at 1.75 million people. In addition, more than 200,000 new cases are diagnosed annually in the U.S.

About Primary Open Angle Glaucoma (POAG)

The cause for increase in intraocular pressure is not fully understood. Several large studies have shown that eye pressure is a major risk for damaging the optic nerve, In the front of the eye is a space called the anterior chamber. A clear fluid (called aqueous humor) flow continuously in and out of the chamber and nourishes nearby tissues. The fluid leave the chamber at the open angle where the cornea and iris meet. When the fluid reaches the angle, it flows through a spongy network, like a drain, and leaves the eye. In POAG, the fluid passes too slowly through the meshwork drain, causing the fluid to build up and increasing pressure in the eye that may damage the optic nerve. When the optic nerve is damaged from increased pressure, vision loss may result. Currently, the most common form of treatment is use of eye drops that contain drugs to lower the pressure in the eye that must be taken every day. However, many patients have difficulty using or remembering to administer the eye drops. Graybug is developing technology whereby the physician periodically administers the drug instead (“dropless” technology) with the intent to reduce the pressure in the eye over several months. Our goal is to reduce or eliminate the need for eye drops to manage the disease altogether.

About Graybug Vision

Graybug Vision is developing novel products for the treatment of people with ocular diseases. The company’s proprietary injectable products are designed to enable less frequent administration and to reduce the burden of treatment for patients with ocular diseases. The company’s lead product, GB-102, has the potential for twice per year injections to treat patients with neovascular (wet) AMD. Graybug Vision has developed a library of compounds to treat glaucoma, a leading cause of progressive, irreversible vision loss worldwide, by lowering intraocular pressure alone or in combination with neuroprotection when injected twice per year into the subconjunctiva. For more information, please visit www.graybug.com.

Contacts

Investors/Media
Jeff Cleland, 650-487-2808
jcleland@graybug.com

Release Summary

Graybug Vision to Participate in Upcoming Industry Conferences

Contacts

Investors/Media
Jeff Cleland, 650-487-2808
jcleland@graybug.com